Oncology & Cancer

Blocking an enzyme may improve melanoma immunotherapy outcomes

About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in a specific subset of ...

page 5 from 40